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patients. PVI success and complication rates were similar between SHD and NHP. Con-
clusions: SHD does not affect outcomes of PVI for treatment of AF; its presence should
not preclude ICE/circular mapping guided PVI. * p < 0.05
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1129-209 Incidence of Cerebral Embolism After Cardioversion of 
Atrial Fibrillation: A Prospective and Serial Study Using 
Magnetic Resonance Imaging
Harald Schmidt, Peter Bernhardt, Christoph Hammerstingl, Stefan Illien, Christina 
Münsel, Torsten Sommer, Berndt Lüderitz, Heyder Omran, University of Bonn, Bonn, 
Germany
Background: The incidence of clinical apparent cerebral embolism in patients (pts) with
atrial fibrillation (AF) who underwent transesophageal echocardiographical (TEE) guided
cardioversion is approximately 1%. The incidence of clinically silent cerebral embolism
has not been analysed yet. The aims of this prospective studies were (1) to evaluate the
prognosis of cardioversion in pts with AF and (2) to assess the incidence of cerebral
embolism with MR-imaging (MRI).
Methods: The study group consisted of 102 pts with AF and TEE guided cardioversion.
To document the incidence of cerebral embolism all pts received oral anticoagulation
therapy (an INR > 2 was defined as effectively anticoagulated), neurological assessment
and cranial MRI including diffusion- weighted imaging within <24h before , <48h and 4
weeks after the procedure.
Results: 76 (75%) pts had sinus rhythm in the 4 weeks follow-up assessment. There
were no clinical apparent cerebral embolism. 2 (2%) pts had acute cerebral microembo-
lism in the MRI during the follow-up period. 59 (58%) pts were effectively anticoagulated
during the observation period. One patient with acute cerebral lesion in the MRI was not
effectively anticoagulated.
Conclusions: The incidence of clinically silent embolism after TEE guided cardioversion
in pts with AF under continued effective anticoagulation is low. The findings of this study
support the safety of the TEE guided approach to cardioversion in AF patients.
1129-210 Incidence of Cerebral Embolism in High-Risk Patients 
With Atrial Fibrillation
Harald Schmidt, Peter Bernhardt, Christoph Hammerstingl, Matthias Hackenbroch, 
Torsten Sommer, Berndt Lüderitz, Heyder Omran, University of Bonn, Bonn, Germany
Background: Patients (pts) with atrial fibrillation (AF) and spontaneous echo contrast
(SEC) have an increased stroke risk. The aims of this prospective study were (1) to eval-
uate the prognosis of pts with dense SEC and (2) to assess the incidence of cerebral
embolism with MR-imaging (MRI) under continued oral anticoagulation therapy.
Methods: The study group consisted of 64 pts with SEC and AF. 28 pts served as con-
trols. All pts received oral anticoagulation therapy during the follow-up period (an INR > 2
was defined as effectively anticoagulated). To document the incidence of cerebral embo-
lism all pts underwent the following examinations at admission and at 1, 3 and 12
months: transthoracic and transesophageal echocardiography, cranial MRI including dif-
fusion- weighted MRI, assessment of the anticoagulation level and neurological assess-
ment.
Results: 2 pts had clinically silent cerebral embolism at the index examination. Two
patients (3%) had cerebral embolism with neurological deficit during the follow-up period.
Four (6%) pts died during the observation period due to stroke. Additionally, 6 (9%) pts
had new appeared focal diffusion abnormalities in the MRI during the follow-up. 45 (70%)
pts were effectively anticoagulated, 15 (23%) pts were anticoagulated inadequately dur-
ing the 12 months. Pts with cerebral embolism had lower left atrial appendage peak
empty velocities (0.22 ± 0.14 vs. 0.38 ± 0.21; p<0.01) and denser SEC (2.8 ± 1.1 vs. 1.6
± 1.4; p<0.01) than pts without cerebral events.
Conclusions: Pts with AF and SEC have an increased risk of cerebral embolism despite
oral anticoagulation therapy. Low peak empty velocities of the left atrial appendage and
dense SEC are echocardiographic predictors for a cerebral event.
1129-211 Cardioversion for Chronic Atrial Fibrillation Is 
Associated With an Immediate Drop in Brain Natriuretic 
Peptide
Craig S. Vinch, Jason Rashkin, Giridhar Logsetty, Dennis A. Tighe, Jeffrey C. Hill, Theo 
E. Meyer, Lawrence S. Rosenthal, Gerard P. Aurigemma, University of Massachusetts 
Medical School, Worcester, MA, Brigham & Women's Hospital, Boston, MA
Background: Atrial fibrillation (AF) is often associated with heart failure (HF) symptoms,
even in patients with normal ejection fraction (EF). Since brain natriuretic peptide (BNP)
levels are elevated in HF, we hypothesized that BNP elevations in pts with AF would cor-
relate with HF symptoms, but would not fall immediately following cardioversion (CV),
since atrial mechanical function would not yet be restored. Accordingly, we studied BNP
in pts pre- and post CV, controlling for possible effects of conscious sedation (IVCS).
Methods: We enrolled 50 consecutive pts (39 male, 11 female, age 62 ± 14) undergoing
CV, with mean EF 54% ± 12: 38 pts had EF >50%; 17 consecutive pts (12 male, age 61
± 16 years) receiving IVCS for non-AF related TEE served as controls. Results:Pre-CV
BNP exceeded 100 pg/ml in 36/50 (72%) pts, and tended to correlate with HF symptoms
(p=0.06). BNP fell immediately following CV in 36/49 (73%). By contrast, BNP rose in
association with IVCS in 13/16 (81%) controls. Summary/Conclusions: BNP (1) is ele-
vated in chronic AF, despite normal EF and (2)correlates with number of HF symptoms,
likely reflecting elevated filling pressures and/or neurohumoral activation; surprisingly (3)
BNP falls in most pts immediately following CV, but this fall (4) does not appear to be due
to IVCS. Given the rapidity of the fall in BNP, we speculate that CV-associated drop in
BNP likely reflects the salutary effects of rhythm uniformity rather than reestablishment of
atrial kick. 
1129-212 Endothelial, Coagulation, and Platelet Function in Atrial 
Fibrillation: Effect of Direct Current Cardioversion
Fraser Witherow, Neil Grubb, Christopher Ludlam, Keith A. Fox, Andrew D. Flapan, 
Cardiovascular Research, Edinburgh, United Kingdom
Background. Atrial fibrillation (AF) is the most common human arrhythmia with a preva-
lence in the elderly population of up to 15%. It results in breathlessness, palpitations and
systemic embolisation due to a procoagulant state. Recent studies of AF have suggested
that rate control with anticoagulation may have a superior outcome compared to rhythm
control. The aim of this study was to assess the effect of D.C. cardioversion on markers of
coagulation and platelet activity and endothelial function in patients with AF on warfarin
therapy.
Methods Sixty patients undergoing elective D.C cardioversion for non-valvular atrial
fibrillation were recruited to the study. All patients were taking warfarin aiming for an INR
of 2-3. D.C cardioversion was performed under general anaesthetic following our local
protocol. Peripheral venous blood was sampled through a 16G needle prior to cardiover-
sion and at 2,4,6 and 10 weeks post cardioversion provided they remained in sinus
rhythm (SR). Warfarin was discontinued 6 weeks after cardioversion. The samples were
assayed for INR, prothrombin fragment 1+2, d-dimer, beta thromboglobulin, and von Will-
iebrand factor.
Results. Nine patients failed to cardiovert to sinus rhythm, and 8 people withdrew from
the study. Median age was 65 (39-77) years. Mean INR was 2.4±0.3. At 2 weeks, 20
patients remained in SR and 23 had reverted to AF. Compared to baseline, D.C. cardio-
version produced no significant change in prothrombin fragment 1+2 (p=0.1), d-dimer
(p=0.3), beta thromboglobulin (p=0.3), or von Williebrand factor (p=0.6). No significant
change in coagulation or platelet activity was seen at 4 weeks (n=15) or 6 weeks (n=18),
compared to baseline. At 10 weeks, once warfarin was discontinued, only prothrombin
fragment 1+2 levels were higher than at baseline (p=0.009).
NHP SHD EF<40% VD CVS
N 194 183 94 102 26
Age, y 54±12 56±11 54±1 58±10* 61±11*
Left atrial size, cm 4.4±2.4 4.7±1.8 4.7±0.6 4.7±2.0 4.9±0.3*
NYHA 1 1.4 1.6 1.4 1.5
Fluoro time, min 83±26 87±20 89±20* 85±20 87±22
Procedure time, h 4±1 4±1 5±1* 4±1 4±1
Neurologic Event 1 3 3 1 0
Tamponade 4 0 0 0 0
Access Site Hematoma 1 1 0 1 0
Severe PV Stenosis 2 2 1 1 0
Recurrence 31 27 25 17 2
2nd PVI 27 21 21 12 1
Overall Success, % 98 95 95 93 96
Follow-up, months 18±7 12±6 13±5 11±5 11±6
